Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross SC Medicare Part D Coverage Update | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    BlueCross Total Medicare Part D Formulary — Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the BlueCross Total (BlueCross BlueShield of South Carolina) Medicare Part D formulary describing covered drugs, coverage rules, restrictions (prior authorization, step therapy, quantity limits), and how members can request exceptions. It affects plan members, prescribers, and network pharmacies using BlueCross Total prescription drug benefits.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyBlueCross Total Medicare Part D Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeTechnical/periodic update (no material changes)
    Effective DateMar 1, 2026
    Last ReviewFeb 2, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when 'PA' or 'PA NSO' appears next to a drug to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    02/02/2026formulary last updated
    03/01/2026effective date
    30dadvance notice
    72hnormal decision time
    24hexpedited decision time
    multiplePA frequency in extract

    Coverage Criteria & Rules

    General coverage conditions

    Covered when ALL of the following general conditions are met

    coverage_general: Drug is listed on the BlueCross Total formulary; the prescription is filled at a BlueCross Total network pharmacy; and other plan rules are followed.

    See formulary chart for drug-specific requirements (prior authorization, quantity limits, step therapy).

    Temporary transition coverage

    Covered temporarily under limited circumstances

    temporary_coverage: During the first 90 days of membership, for drugs not on the formulary or with restrictions, the plan will cover a temporary 30-day supply; for long-term care residents past 90 days with limited access, a 31-day emergency supply may be provided while pursuing a formulary exception.30 days / 31 days

    Outpatient discharge supplies may be provided to prevent a gap in care; refill rules apply to limit the temporary supply to a maximum 30 days for new members.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyBlueCross Total Medicare Part D Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeTechnical/periodic update (no material changes)
    Effective DateMar 1, 2026
    Last ReviewFeb 2, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when 'PA' or 'PA NSO' appears next to a drug to avoid claim denial.
    SourceLink
    On This Page
    Coverage Criteria & RulesProvider Actions, Prior Authorization & ProcessDrug Listings & Code TablesContinuation & Transition RulesStep Therapy RulesQuantity Limits (per-product examples)Mail Order & Long-Term Care (LTC) GuidanceDefinitions & Requirements/Limits KeyBackground & Scope

    Coverage flags and administrative requirements

    Products listed are assigned drug tiers and may have one or more of the following requirements/limits:

    Requirements types: PA (Prior Authorization), QL (Quantity Limit), NDS (notation used in table) may apply depending on the product; see Requirements/Limits column for each product.

    This excerpt does not provide the clinical entry criteria to meet PA or NDS; refer to the formulary introduction or specific PA policies for required documentation and clinical criteria.

    Coverage indicators (Tier / PA / QL)

    Drugs are listed with Tier and any Requirements/Limits; PA and QL annotations indicate additional authorization or quantity controls.

    Formulary listing: Each drug line includes Drug Tier and Requirements/Limits; if 'PA' is present prior authorization is required; if 'QL(...)' is present quantity limits apply.

    This segment does not include clinical entry criteria beyond PA/QL annotations.

    If a medication is not listed on the BlueCross Total formulary, coverage will not be provided unless an exception is approved. Members or prescribers should first contact Customer Service to confirm whether an alternative covered drug exists. If a covered therapeutic alternative is available, prescribers are encouraged to consider switching to that product to obtain coverage under the plan. If no suitable alternative is acceptable, the prescriber or member may request a formulary exception for the non‑formulary drug; instructions for how to request an exception are provided in the formulary (see exception request guidance).

    Provider Actions, Prior Authorization & Process

    Prior Authorization

    Prior authorization required for some drugs

    Certain drugs listed on the formulary require prior authorization from BlueCross Total before the prescription is filled; check the Requirements/Limits column on the formulary for PA indicators to determine if authorization is required for a given product. Failure to obtain required prior authorization may result in non-coverage of the drug.

    • PA indicator shown in Requirements/Limits column denotes prior authorization is required.
    • Prescribers must submit PA per the plan's PA process before dispensing when 'PA' or 'PA NSO' is present.
    Prior Authorization

    Prior Authorization requirement

    Prior authorization (PA) is required for drugs marked 'PA' in the Requirements/Limits Key and for individual drug entries that list PA; examples in the formulary include diclofenac sodium external solution 1.5% and other line items annotated 'PA'.

    • Refer to the Requirements/Limits Key: 'PA = Prior Authorization'.
    • Individual drug rows showing 'PA' (Requirements/Limits) require prescriber submission of PA.
    Prior Authorization

    Prior authorization required for some listed products

    Some specific products in the extract display PA in their Requirements/Limits column (for example, fentanyl oral transmucosal lozenges and ARIKAYCE); providers must obtain PA prior to dispensing those products.

    • Fentanyl oral transmucosal lozenge entries show 'Requirements/Limits = PA; NDS'.
    • ARIKAYCE SUSPENSION 590MG/8.4ML is listed with 'Requirements/Limits = PA'.
    Prior Authorization

    Prior authorization required for flagged products

    Certain specialty or brand products are flagged 'PA NSO' in the formulary; when 'PA NSO' appears next to a product, prior authorization must be obtained before coverage will be approved.

    • 'PA NSO' entries (e.g., BRIVIACT formulations, EPIDIOLEX, SPRAVATO) indicate prior authorization is required.
    • Providers must follow the plan's PA process for PA NSO products before dispensing.
    Prior Authorization

    Prior authorization required for specified drugs

    Multiple listed products are designated 'PA' or 'PA NSO' in their Requirements/Limits field, indicating prior authorization must be obtained before coverage is approved for those specific drugs.

    • Examples include SPRAVATO therapy packs and numerous specialty agents annotated with PA NSO or PA.
    • Check each product row for the 'PA' or 'PA NSO' annotation to determine PA requirement.
    Prior Authorization

    Prior authorization (PA NSO) required for many listed drugs

    Many specialty and oncology drugs in this formulary excerpt are marked 'PA NSO', meaning prior authorization (with NSO modifier) is required and providers must obtain authorization per the plan's PA process.

    • Examples: POMALYST, THALOMID, INLURIYO, and other oncology agents are listed with 'PA NSO'.
    • PA NSO entries require prescriber submission of prior authorization prior to dispensation.
    Prior Authorization

    Prior authorization required for many Tier 5 drugs

    Numerous Tier 5 and other high-cost drugs are annotated with 'PA' or 'PA NSO' in the Requirements/Limits column; providers must obtain PA before dispensing when indicated to avoid denial.

    • Many Tier 5 entries (e.g., oncology and specialty agents) show PA NSO or PA in their rows.
    • Prescribers should submit PA documentation per plan requirements for Tier 5 drugs when PA is indicated.
    Prior Authorization

    Prior authorization required for specified products

    Certain high-tier or specialty products are specifically designated 'PA' in the Requirements/Limits column (examples include MAVYRET, sofosbuvir/velpatasvir, VOSEVI, MOUNJARO, OZEMPIC); obtain PA before coverage is approved for those products.

    • MAVYRET and sofosbuvir/velpatasvir entries show QL and PA annotations.
    • MOUNJARO and OZEMPIC rows include QL and PA indicators — submit PA per formulary guidance.
    Prior Authorization

    PA required for annotated products

    Drugs annotated 'PA' in the Requirements/Limits column require prior authorization; review the product row annotations and submit PA per the plan's process for any 'PA' entries.

    • Examples in this segment: MOUNJARO, OZEMPIC, TRULICITY, RYBELSUS are annotated with PA.
    • PA annotation in the product row is actionable—providers must request authorization before dispensing.
    Prior Authorization

    Prior authorization / quantity limits required

    Selected branded and specialty products require prior authorization and/or have quantity limits as annotated in the Requirements/Limits column; providers must both obtain PA where shown and ensure dispensed quantities do not exceed listed QLs.

    • Examples: metyrosine capsule 250mg (PA); ENTRESTO CAPSULE SPRINKLE QL(240 EA per 30 days); PRALUENT QL(2 ML per 28 days) with PA.
    • Claims exceeding QL may require PA or be denied—confirm QL on the product row before adjudication.
    Prior Authorization

    Prior Authorization required for listed PA drugs

    Several specialty and high-cost products listed with 'PA' require prior authorization; check each product row for PA indications and submit required documentation before dispensing to avoid claim denial.

    • REPATHA and PRALUENT entries include QL and PA annotations.
    • SPEVIGO and other specialty injectables show both QL and PA requirements.
    Prior Authorization

    PA for specialty agents

    Multiple specialty agents used in conditions like multiple sclerosis and dermatology are listed with PA indicators (e.g., AVONEX, BETASERON, glatiramer acetate, KESIMPTA, VUMERITY); prescribers must request PA per the formulary row when PA is present.

    • Glatiramer acetate injections and KESIMPTA include QL and PA in their rows.
    • Submit PA according to the plan's PA process for these specialty agents before dispensing.
    Prior Authorization

    Prior authorization required for specific drugs

    Some specific high-tier products (for example SPEVIGO INJECTION) list 'PA' in their Requirements/Limits and will require prior authorization documentation to be submitted before coverage is approved.

    • SPEVIGO INJECTION 150MG/ML, 300MG/2ML shows QL(4 ML per 28 days); PA.
    • OTEZLA, JYNARQUE, LIVMARLI and other high-tier products are annotated with PA—submit supporting documentation with PA request.
    Prior Authorization

    Prior authorization required where 'PA' indicated

    When a product row lists 'PA' next to Requirements/Limits (e.g., LIVMARLI formulations), prior authorization is required for coverage; providers must submit PA per the plan's process prior to dispensing.

    • LIVMARLI solutions and tablets include QL and PA annotations (e.g., QL(60 ML per 30 days); PA).
    • Check product row annotations for PA and corresponding QL before submitting claims.
    Prior Authorization

    Prior authorization required for selected injectable/specialty agents

    Several injectable hormonal agents and other specialty injectables are marked with PA or PA NSO and/or quantity limits (e.g., FIRMAGON, LUPRON DEPOT, ORGOVYX, SIGNIFOR); obtain PA according to the Requirements/Limits annotation before dispensing.

    • FIRMAGON Injection entries include QL and PA NSO annotations.
    • LUPRON DEPOT entries show QL and PA NSO across multiple dose intervals—submit PA for these injectable products as indicated.
    Prior Authorization

    Prior authorization required for many products

    Numerous products across the formulary require prior authorization as indicated next to product rows; prescribers must obtain PA prior to dispensing to avoid claim denial for those items.

    • Multiple entries across the formulary include PA or PA NSO markers—review each product row for PA requirements.
    • PA must be obtained according to the plan's PA process before dispensing PA-marked drugs.
    Step Therapy

    Step therapy requirements

    Step therapy may require that prescribers document and demonstrate prior use of specified first-line drugs before the plan will cover alternative agents; check product rows and the Requirements/Limits Key for ST or ST NSO indicators.

    • ST and ST NSO symbols in the Requirements/Limits Key denote step therapy requirements.
    • If a drug is marked with ST or ST NSO, prior therapeutic steps must be documented to support coverage.
    Note

    Step therapy indicators

    Step therapy abbreviations (e.g., ST NSO) appear in the Requirements/Limits Key and product rows; ST NSO indicates 'Step Therapy for New Starts Only' and may limit PA applicability to new starts.

    • Reference the Dosage/Requirements Abbreviation Key for the meaning of ST NSO and related symbols.
    • Providers should consult the introduction pages for exact interpretation of ST and ST NSO indicators.
    Note

    Step therapy not specified in this excerpt

    This extract does not provide explicit step-therapy sequences or detailed fail-first rules for most products; where step therapy is applicable the product row will show ST or ST NSO and providers should consult the formulary introduction or related PA/ST policy pages for the required sequence.

    • No explicit step sequences are listed in these chunks for most products.
    • Consult the formulary introduction or the plan's PA/step therapy policies for specific step requirements.
    Step Therapy

    Step therapy examples

    Examples in the formulary show 'ST NSO' markers on certain products (e.g., ZONISADE suspension, AUVELITY, EXXUA, FETZIMA) indicating step therapy applies for new starts; providers must document prior steps per the Requirements/Limits annotation when submitting for coverage.

    • ZONISADE SUSPENSION 100MG/5ML is listed with 'ST NSO'.
    • FETZIMA entries include ST NSO and QL annotations—follow Requirements/Limits when requesting coverage.
    Step Therapy

    Step therapy indicated for some products

    Some products are marked 'ST' or 'ST NSO' (for example FETZIMA and diclofenac sodium gel 3%), indicating step therapy requirements exist; providers must document prior steps when requesting coverage under these markers.

    • diclofenac sodium gel 3% is annotated 'ST' in the product row.
    • For products with 'ST' or 'ST NSO' the plan expects documentation of prior therapy per the formulary rules.
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    Product-specific labeling restrictions

    Certain product-specific labeling restrictions and starter-pack limits are called out (for example, Boehringer Ingelheim labeled ADALIMUMAB-ADBM starter packages), which may impose PA and QL conditions; providers should follow the formulary's Requirements/Limits and labeled-product notes when submitting authorization requests.

    • ADALIMUMAB-ADBM starter packages include QL and PA with 'Boehringer Ingelheim labeled products only' notation.
    • Product-specific labeling or starter-pack restrictions must be observed when requesting PA or processing claims.
    Documentation Required

    Prescriber's supporting statement and decision timelines

    When requesting an exception, the prescriber must provide a supporting statement explaining medical necessity; the plan generally must decide within 72 hours of receiving the prescriber's statement (24 hours for expedited requests).

    • Standard decision timeline: 72 hours after receipt of prescriber's supporting statement.
    • Expedited decision timeline (when agreed): 24 hours after receipt of prescriber's supporting statement.
    Documentation Required

    Site-specific coverage documentation (LTC/mail order guidance)

    For Long-Term Care (LTC) and mail-order claims, site-specific supply and copay/coinsurance rules apply (e.g., LTC = 31-day supply); providers should use the formulary's site-of-care guidance for correct benefit application.

    • Long-Term Care (LTC) supply is defined as a 31-day supply in the formulary.
    • Mail order and LTC copay/coinsurance differ from retail—use site-of-care rules when adjudicating claims.
    Documentation Required

    Formulary reference (ID/version)

    Reference the formulary identifier and version (Formulary ID: 26216, Version: 10, Effective Date: 03/01/2026; Last Updated: 02/02/2026) when submitting or verifying authorizations and coverage determinations.

    • Formulary ID: 26216, Version: 10; Effective Date: 03/01/2026; Last Updated: 02/02/2026.
    • Include this formulary/version information as needed when filing authorizations or appeals.
    Billing Rule

    Quantity limit examples

    Quantity limits (QL) shown on product rows must be observed; examples in the formulary include NAYZILAM QL(10 EA per 30 days) and memantine/donepezil QL(30 EA per 30 days).

    • Check the product row for QL(...) notation and ensure dispensed quantity does not exceed the listed limit without prior authorization.
    • Exceeding QL may require PA or may be denied at claim adjudication.
    Documentation Required

    Reference to introduction pages for symbols/abbreviations

    The formulary introduction pages define the symbols and abbreviations used in product rows (e.g., PA, QL, ST, NDS, PA NSO); providers should consult those introduction pages for precise meanings and documentation expectations.

    • Introduction explains Requirements/Limits Key and dosage/abbreviation symbols.
    • Interpretation of ST NSO, PA NSO and other markers requires reference to the introduction.
    Documentation Required

    PA NSO requires prior authorization (documentation specifics not included)

    When a drug line lists 'PA NSO' the plan requires prior authorization (PA NSO = Prior Authorization — Non-State Only); this excerpt does not include the specific documentation elements required for PA NSO requests, so providers must follow the plan's PA submission guidance.

    • 'PA NSO' entries indicate PA is required (examples: POMALYST, BRIVIACT, EPIDIOLEX).
    • Specific documentation requirements for PA NSO are not detailed in this extract—refer to the plan's PA instructions.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Prior Authorization

    PA submission (providers must submit per PA process)

    Prescribers must submit prior authorization requests for drugs marked 'PA' and support those requests consistent with the plan's PA process and the introduction pages referenced in the formulary.

    • Submit PA according to the plan's PA process when 'PA' is indicated on the product row.
    • Include clinical justification and any requested supporting documents per PA instructions.
    Denial Risk

    Failure to obtain required prior authorization may result in non-coverage

    Failure to obtain required prior authorization may result in the plan not covering the drug; providers should obtain PA before dispensing PA-marked drugs to avoid claim denials.

    • If prior authorization is required but not obtained, the plan may deny coverage for the drug.
    • Confirm PA status on the product row and obtain authorization prior to dispensing when indicated.
    Prior Authorization

    Prior authorization triggers

    Prior authorization is triggered by PA markers in the Requirements/Limits Key and by PA annotations in individual drug entries (e.g., diclofenac sodium external solution 1.5% is listed with 'PA'); providers should check these markers to identify PA triggers.

    • 'PA' in the Requirements/Limits Key signals a PA trigger.
    • Individual product rows annotated with 'PA' or 'PA NSO' trigger PA submission requirements.
    Prior Authorization

    PA/NDS required for some opioid products

    Some opioid products (e.g., fentanyl transmucosal lozenges) include PA and NDS annotations ('PA; NDS'); claims for these items may require PA or special handling and could be denied without required authorizations.

    • Fentanyl citrate oral transmucosal lozenge entries show 'PA; NDS'.
    • Claims for opioid products annotated with PA/NDS may be denied or require PA/override handling if authorization is not obtained.
    Prior Authorization

    PA for ARIKAYCE

    ARIKAYCE SUSPENSION 590MG/8.4ML is listed with 'Requirements/Limits = PA' and may be denied without PA documentation; obtain and submit prior authorization before dispensing ARIKAYCE.

    • ARIKAYCE row explicitly indicates 'PA' in Requirements/Limits.
    • PA documentation must be submitted prior to dispensing to avoid denial.
    Denial Risk

    Prior authorization risk examples

    Products labeled 'PA NSO' (examples: BRIVIACT formulations, EPIDIOLEX, DIACOMIT, vigabatrin products, XCOPRI packs) indicate prior authorization is required and may lead to denial if PA is not obtained.

    • BRIVIACT and EPIDIOLEX entries are annotated 'PA NSO'.
    • XCOPRI therapy packs are listed with 'PA NSO'—submit PA accordingly.
    Prior Authorization

    Prior authorization required for PA/PA NSO entries

    Claims for drugs listed with 'PA' or 'PA NSO' will require prior authorization; lack of authorization may trigger claim denial—providers must obtain PA before dispensing when these annotations are present.

    • PA/PA NSO in product rows indicates authorization requirement.
    • Confirm PA status and secure authorization to prevent claim denials.
    Denial Risk

    Quantity limit exceedance may result in denial or need for PA

    Exceeding a product's specified quantity limit (QL) may result in claim denial or require prior authorization; providers should verify QL values on the product row before dispensing larger quantities.

    • PAXLOVID QL is specified per 5-day therapy packs—exceeding listed QL could trigger denial or review.
    • Many products list explicit QL(...) values—ensure dispensed quantities comply or obtain PA to exceed limits.
    Prior Authorization

    Prior authorization required where PA NSO indicated

    Where product rows list 'PA NSO', prior authorization is required and claims may be denied or require special handling if PA NSO is not obtained (examples across oncology and specialty drug listings).

    • PA NSO entries (e.g., many oncology agents) require PA prior to dispensing.
    • Providers should follow PA submission instructions for PA NSO products to avoid denial.
    Denial Risk

    Claims or dispensings for listed drugs may be denied if PA/NSO conditions are not met

    Claims or dispensings for listed drugs may be denied if prior authorization (PA) requirements or non-standard override (NSO) conditions are not met; providers must confirm PA/NSO annotations and obtain approvals as required.

    • Many Tier 5 drugs list PA NSO and will require PA/NSO handling before coverage.
    • Failure to meet PA/NSO conditions may lead to claim denial at adjudication.
    Prior Authorization

    Prior authorization noted in table (examples MAVYRET, VOSEVI)

    The formulary table includes numerous examples where PA is noted inline for specific products (for instance MAVYRET and VOSEVI show QL and PA); providers must consult those rows and obtain PA when shown.

    • MAVYRET PACKET: QL(560 EA per 365 days); PA.
    • sofosbuvir/velpatasvir and VOSEVI entries include QL and PA annotations—submit PA as required.
    Billing Rule

    Quantity-limit enforcement (PAXLOVID example)

    Quantity-limit enforcement is applied to certain products (PAXLOVID therapy packs include multiple QL variants per 5-day course); dispensing beyond the listed QL may trigger denial or require prior authorization.

    • PAXLOVID entries show QL(11-30 EA per 5 days) depending on pack size—adhere to the listed QL.
    • If a requested dispensing exceeds QL, obtain PA or expect claim review/denial.
    Prior Authorization

    Prior authorization required for marked products (GLP‑1 examples)

    Coverage may be denied without prior authorization for products marked 'PA' such as MOUNJARO, OZEMPIC, TRULICITY, RYBELSUS and other GLP‑1 or injectable agents; obtain PA and adhere to the listed QLs prior to dispensing.

    • MOUNJARO INJECTION 10MG/0.5ML = QL(2 ML per 28 days); PA.
    • OZEMPIC INJECTION 2MG/3ML = QL(3 ML per 28 days); PA.
    Billing Rule

    Quantity limits enforcement (GLP‑1 / tablet examples)

    Exceeding quantity limits for products with QL annotations (for example QL(2 ML per 28 days) for MOUNJARO; QL(3 ML per 28 days) for OZEMPIC; QL(30 EA per 30 days) for certain tablets) may trigger claims denial or require prior authorization.

    • Observe per-product QL entries when dispensing injectables and tablets.
    • Requests above QL require PA or may be denied at claim adjudication.
    Prior Authorization

    Prior authorization triggers (selected cardiovascular and specialty agents)

    Some drugs are listed with 'PA' in the Requirements/Limits column (e.g., metyrosine capsule 250mg; NEXLETOL/NEXLIZET; PRALUENT; REPATHA; VYNDAMAX; KERENDIA); these annotations trigger a PA requirement and possible denial if authorization is not obtained.

    • metyrosine capsule 250mg = PA.
    • NEXLETOL and NEXLIZET: QL(30 EA per 30 days); PA.
    Prior Authorization

    PA indicated for listed drugs (cardiology/lipid examples)

    Coverage may be denied or subject to prior authorization for products listed with 'PA' such as NEXLETOL, NEXLIZET, PRALUENT, REPATHA products and VERQUVO; obtain PA and respect any stated quantity limits when submitting claims.

    • PRALUENT injection lists QL(2 ML per 28 days); PA.
    • REPATHA entries include QL and PA—submit PA with required documentation.
    Denial Risk

    Authorization/denial triggers (PA/ST/QL)

    Products listed with 'PA' or with utilization flags such as 'ST' or 'QL' may be denied if prior authorization, step-therapy criteria, or quantity limits are not met; providers must document compliance with the applicable Requirements/Limits to avoid denials.

    • SPEVIGO INJECTION: QL(4 ML per 28 days); PA — authorization required.
    • RELISTOR entries show QL and ST annotations—ensure step or PA criteria are met.
    Prior Authorization

    Prior authorization required for specified products (LIVMARLI example)

    Claims for listed products may be denied without prior authorization where PA is indicated (examples include LIVMARLI solutions/tablets and other specialty agents); confirm PA requirements and obtain authorization before dispensing.

    • LIVMARLI solutions and tablets list QL and PA annotations (e.g., QL(60 ML per 30 days); PA).
    • Specialty agents with PA annotations require prior approval to be covered.
    Denial Risk

    Products marked with PA/PA NSO and QL are at risk for denial without PA

    Products marked with PA or PA NSO and specific QL entries are at risk for denial if prior authorization is not obtained or QL is exceeded; providers should verify both PA and QL annotations on the formulary rows before dispensing.

    • Examples: OSPHENA QL(30 EA per 30 days); PA and FIRMAGON with QL and PA NSO.
    • When both PA and QL are present, ensure authorization covers the requested quantity.
    Prior Authorization

    Prior authorization required (general)

    Coverage requests for drugs listed with 'PA' (Prior Authorization) may be denied if prior authorization is not obtained as indicated in the formulary rows; prescribers must request PA per the plan's process to secure coverage.

    • If a product row shows 'PA', submit PA prior to dispensing to avoid denial.
    • Follow the plan's PA submission instructions and include required clinical documentation.

    Drug Listings & Code Tables

    Opioid transmucosal lozengesNDCCovered
    200mcgfentanyl citrate oral transmucosal lozenge on a handle 200mcg (Requirements/Limits = PA; NDS)
    400mcgfentanyl citrate oral transmucosal lozenge on a handle 400mcg
    600mcgfentanyl citrate oral transmucosal lozenge on a handle 600mcg
    800mcgfentanyl citrate oral transmucosal lozenge on a handle 800mcg
    1200mcgfentanyl citrate oral transmucosal lozenge on a handle 1200mcg
    1600mcgfentanyl citrate oral transmucosal lozenge on a handle 1600mcg
    Specific branded inhaled antibioticNDCCovered
    ARIKAYCE SUSPENSION 590MG/8.4MLARIKAYCE SUSPENSION 590MG/8.4ML (Requirements/Limits = PA)
    Antibacterial products with QLNDCCovered
    LINEZOLID SUSPENSION 100MG/5MLlinezolid suspension reconstituted 100mg/5ml (Requirements/Limits = QL(1800 ML per 28 days))
    LINEZOLID TABLET 600MGlinezolid tablet 600mg (Requirements/Limits = QL(56 EA per 28 days))
    VANCOMYCIN CAPSULE 125MGvancomycin hydrochloride capsule 125mg (Requirements/Limits = QL(120 EA per 30 days))
    VANCOMYCIN CAPSULE 250MGvancomycin hydrochloride capsule 250mg (Requirements/Limits = QL(240 EA per 30 days))
    Document identifiersmixed
    Formulary ID: 26216Formulary identifier and version
    Example drug entries with tiers and requirementsNDC|mixed
    POMALYST CAPSULE 3MG, 4MGTier = 5; Requirements/Limits = PA NSO
    POMALYST CAPSULE 1MG, 2MGTier = 5; Requirements/Limits = QL(30 EA per 30 days); PA NSO
    THALOMID CAPSULE 50MG,100MG,150MG,200MGTier = 5; Requirements/Limits = PA NSO
    EMCYT CAPSULE 140MGTier = 5; Requirements/Limits = .
    INLURIYO TABLET 200MGTier = 5; Requirements/Limits = PA NSO
    Selected product identifiers (formulary entries)mixed
    PAXLOVID TABLET THERAPY PACK 150MG; 100MGPAXLOVID tablet therapy pack (Requirements/Limits include QL variants per pack: QL(11 EA per 5 days); QL(20 EA per 5 days); QL(30 EA per 5 days))
    GLP-1 receptor agonist injectablesmixed
    MOUNJARO INJECTION 10MG/0.5MLMOUNJARO INJECTION 10MG/0.5ML (Requirements/Limits = QL(2 ML per 28 days); PA)
    OZEMPIC INJECTION 2MG/3MLOZEMPIC INJECTION 2MG/3ML (Requirements/Limits = QL(3 ML per 28 days); PA)
    Quantity limit notations present in this segmentmixed
    QL(30 EA per 30 days)Quantity limit example for JANUVIA and RYBELSUS 14mg/7mg
    QL(2 ML per 28 days)Quantity limit example for MOUNJARO and TRULICITY
    QL(3 ML per 28 days)Quantity limit example for OZEMPIC
    QL(60 EA per 365 days)Quantity limit example for RYBELSUS 3mg
    Formulary drug entries (partial)mixedCovered
    clobetasol propionate foam 0.05%Drug Tier = 2
    clobetasol propionate gel 0.05%Drug Tier = 3
    clobetasol propionate ointment 0.05%Drug Tier = 2
    clobetasol propionate shampoo 0.05%Drug Tier = 4
    desonide cream 0.05%Drug Tier = 3
    desonide ointment 0.05%Drug Tier = 2; QL(120 GM per 30 days)
    desoximetasone cream 0.25%Drug Tier = 3; QL(100 GM per 30 days)
    EUCRISA OINTMENT 2%Drug Tier = 4; PA
    SPEVIGO INJECTION 150MG/ML, 300MG/2MLDrug Tier = 5; QL(4 ML per 28 days); PA
    triamcinolone acetonide cream 0.025%, 0.1%, 0.5%Drug Tier = 1
    1–10 of 20
    1/2
    Formulary product list (no billing codes in this excerpt)mixed
    No codes listed
    lidocaine/prilocaine cream limit
    ProductLidocaine/prilocaine cream 2.5%/2.5%
    Quantity limitQL(30 GM per 30 days)
    Requirement noteQuantity limit shown in Requirements/Limits column; PA may apply per line-item
    lidocaine ointment limit
    ProductLidocaine ointment 5%
    Quantity limitQL(150 GM per 30 days)
    Requirement noteQuantity limit shown in Requirements/Limits column; PA may apply per line-item
    linezolid suspension limit
    ProductLinezolid suspension reconstituted 100mg/5ml
    Quantity limitQL(1800 ML per 28 days)
    TierTier = 5 (per table)
    linezolid tablet limit
    ProductLinezolid tablet 600mg
    Quantity limitQL(56 EA per 28 days)
    TierTier = 4 (per table)
    vancomycin capsule 125mg limit
    ProductVancomycin hydrochloride capsule 125mg
    Quantity limitQL(120 EA per 30 days)
    TierTier = 4 (per table)
    vancomycin capsule 250mg limit
    ProductVancomycin hydrochloride capsule 250mg
    Quantity limitQL(240 EA per 30 days)
    TierTier = 4 (per table)
    Quantity limits (examples)
    Examples (each)QL(30 EA per 30 days); QL(60 EA per 30 days); QL(120 EA per 30 days)
    Volume examplesQL(2160 ML per 30 days); QL(750 ML per 30 days); QL(540 ML per 30 days)
    Extended/annual examplesQL(560 EA per 365 days); QL(336 EA per 365 days)
    Quantity limits examples (30/60/120 EA per 30 days)
    Common unit examplesQL(30 EA per 30 days); QL(60 EA per 30 days); QL(120 EA per 30 days)
    Large-volume exampleQL(750 ML per 30 days)
    Medication-specific exampleQL(750 ML per 30 days); QL(540 ML per 30 days)
    examples of quantity limits (various ML/EA limits)
    Examples (ML/EA)QL(1800 ML per 28 days); QL(2160 ML per 30 days); QL(240 ML per 30 days)
    Tablet examplesQL(56 EA per 28 days); QL(30 EA per 30 days); QL(90 EA per 30 days)
    Cream/ointment examplesQL(100 GM per 30 days); QL(120 GM per 30 days)
    Quantity limits examples (yearly/30-day examples)
    Annual supply examplesQL(560 EA per 365 days); QL(336 EA per 365 days)
    Monthly exampleQL(30 EA per 30 days)
    Course-based exampleQL(11-30 EA per 5 days) (PAXLOVID therapy packs)
    Examples of quantity limits (ML/EA per time period)
    Injectable volume examplesQL(2 ML per 28 days); QL(3 ML per 28 days); QL(7 ML per 28 days)
    Tablet monthly exampleQL(30 EA per 30 days)
    Annual tablet exampleQL(60 EA per 365 days)
    Quantity Limits examples (various formulations)
    Formulation varietyQL entries apply across formulations (creams GM, suspensions ML, tablets EA); see product line for unit
    Topical examplesQL(30 GM per 30 days); QL(150 GM per 30 days); QL(120 GM per 30 days)
    Oral/IV examplesQL(56 EA per 28 days); QL(120 EA per 30 days); QL(240 EA per 30 days)
    Quantity limits examples (GM/ML/EA examples)
    Unit-magnitude examplesQL(30 GM per 30 days); QL(1800 ML per 28 days); QL(240 EA per 30 days)
    Topical/creamsQL expressed in GM per 30 days for creams/ointments
    Liquids and suspensionsQL expressed in ML per 28/30 days for suspensions and solutions
    Examples of quantity limits (various supply periods)
    Supply-period examplesQL(1 EA per 28 days); QL(91 EA per 91 days); QL(1 EA per 168 days)
    Long-acting depot examplesLUPRON DEPOT QL(1 EA per 28/84/112/168 days) as listed
    Ring/IUD examplesESTRING QL(1 EA per 90 days)

    Continuation & Transition Rules

    Continuation Therapy

    Continuation and transition rules

    continuation_rules: If a drug is on the formulary at the beginning of the year and a member is already taking it, the plan generally will not discontinue or reduce coverage during the coverage year except for immediate-change scenarios (for example, market withdrawal or FDA action).

    Immediate substitutions of new generics or biosimilars may occur; affected members may request exceptions. See formulary change notice requirements (30-day notice) and exception process.

    Step Therapy Rules

    Coverage labelDescription / rule
    ST (Step therapy)
    Must try specified first-line drug(s) before coverage for second-line drug is authorized; if the first-line drug fails, the plan will then cover the alternate agent.
    Coverage labelDescription / rule
    ST NSO
    ST NSO = Step Therapy for New Starts Only (indicator shown in Requirements/Limits Key on introduction pages) — step therapy applies only to new starts as defined by the formulary key.
    Coverage labelDescription / rule
    No explicit sequences listed
    The extracted formulary rows in this excerpt show ST/ST NSO flags for certain drugs but do not provide explicit step-by-step (fail‑first) sequences or the clinical steps required to satisfy step therapy; providers must consult the introduction or related PA/step therapy policy for specific step details.
    Product / markerFormulary note
    ZURZUVAE (capsules) - ST NSO
    SPRAVATO therapy packs - PA NSO and ST NSO flags shown (step therapy applies per Requirements/Limits Key)
    ProductRequirements/Limits
    FETZIMA TITRATION PACK
    Requirements/Limits include ST NSO for FETZIMA products (step therapy for new starts only) per the table entries.
    ProductNotes
    POMALYST capsules (1mg,2mg): QL(30 EA per 30 days); PA NSO
    MAVYRET / sofosbuvir-velpatasvir entries: QL and PA annotated; explicit step sequences not provided in this excerpt
    Coverage labelInterpretation
    ST or ST NSO markers present
    Some products are marked 'ST' or 'ST NSO' in the Requirements/Limits column indicating step therapy applies; specific step definitions and required prior steps are referenced on the document's introduction or separate step therapy policy pages.
    Drug / classUtilization management flags
    MAVYRET, VOSEVI, sofosbuvir/velpatasvir (HCV agents)
    Designated with PA and QL annotations in the formulary (e.g., QL(336 EA per 365 days) for MAVYRET; QL(84 EA per 365 days) for sofosbuvir/velpatasvir) indicating utilization management controls.
    Coverage labelWhat provider must do
    PA (Prior Authorization)
    Prior authorization is required where 'PA' or 'PA NSO' is indicated next to a product; prescribers must obtain approval from BlueCross Total before dispensing to avoid claim denial.
    Product groupQuantity / step notes
    ADHD / stimulant products (various) - QLs present
    Multiple ADHD and stimulant formulations include quantity limits (examples: QL(60 EA per 30 days); QL(90 EA per 30 days); QL(120 EA per 30 days)); explicit step therapy requirements are not shown in this excerpt.
    ProductRequirements/Limits
    diclofenac sodium gel 3%
    Listed with Requirements/Limits = QL(300 GM per 30 days); ST — indicates step therapy applies to this topical diclofenac formulation.
    Product / categoryManagement flags
    LUPRON DEPOT; FIRMAGON; other specialty injectables
    Many specialty injectables include PA NSO and QL annotations (e.g., LUPRON DEPOT entries with QL and PA NSO; FIRMAGON QL and PA NSO) suggesting additional step/specialty criteria outside this extract.
    TopicFormulary note
    Starter packs / labeled-product restrictions
    Some starter packages and product presentations are annotated with product-specific restrictions (e.g., Boehringer Ingelheim labeled products only for certain ADALIMUMAB-ADBM starter packages); see Requirements/Limits entries for details.

    Quantity Limits (per-product examples)

    Cablivi — 30 tablets per 30 days
    Formulary noteQuantity limits (QL) are specified in the Requirements/Limits column and must be observed on claims
    Provider actionExceeding a QL may require prior authorization or result in denial
    ReferenceSee introduction pages for definitions of symbols and units
    JOURNAVX TABLET 50MG — 30
    ProductJOURNAVX TABLET 50MG
    Quantity limitQL(30 EA per 90 days)
    TierTier = 4 (per table)
    celecoxib capsule (various strengths) — 60
    ProductCelecoxib capsules (various strengths)
    Quantity limitQL(60 EA per 30 days)
    TierTier = 2 (per table)
    diclofenac sodium gel 1% — 1000
    ProductDiclofenac sodium gel 1%
    Quantity limitQL(1000 GM per 30 days)
    Additional controlST may apply for other diclofenac formulations (see table)
    buprenorphine patch weekly — 4
    ProductBuprenorphine patch weekly (various strengths)
    Quantity limitQL(4 EA per 28 days)
    TierTier = 4 (per table)
    lidocaine/prilocaine cream 2.5%/2.5% — 30
    ProductLidocaine/prilocaine cream 2.5%/2.5%
    Quantity limitQL(30 GM per 30 days)
    TierTier = 2 (per table)
    lidocaine ointment 5% — 150
    ProductLidocaine ointment 5%
    Quantity limitQL(150 GM per 30 days)
    TierTier = 3 (per table)
    linezolid suspension reconstituted 100mg/5ml — 1800
    ProductLinezolid suspension reconstituted 100mg/5ml
    Quantity limitQL(1800 ML per 28 days)
    TierTier = 5 (per table)
    linezolid tablet 600mg — 56
    ProductLinezolid tablet 600mg
    Quantity limitQL(56 EA per 28 days)
    TierTier = 4 (per table)
    vancomycin capsule 125mg — 120
    ProductVancomycin hydrochloride capsule 125mg
    Quantity limitQL(120 EA per 30 days)
    TierTier = 4 (per table)
    vancomycin capsule 250mg — 240
    ProductVancomycin hydrochloride capsule 250mg
    Quantity limitQL(240 EA per 30 days)
    TierTier = 4 (per table)
    varenicline formulations — 504
    ProductVarenicline formulations (including starting month pack)
    Quantity limitQL(504 EA per 365 days)
    TierTier = 4 (per table)
    NICOTROL NS SOLUTION 10MG/ML — 360
    ProductNICOTROL NS SOLUTION 10MG/ML
    Quantity limitQL(360 ML per 365 days)
    TierTier = 4 (per table)
    NAYZILAM solution 5MG/0.1ML — 10 EA
    ProductNAYZILAM solution 5MG/0.1ML
    Quantity limitQL(10 EA per 30 days)
    TierTier = 4 (per table)
    gabapentin capsule 400mg — 270 EA
    ProductGabapentin capsule 400mg
    Quantity limitQL(270 EA per 30 days)
    TierTier = 1 (per table)
    gabapentin capsule 100mg, 300mg — 360 EA
    ProductGabapentin capsule 100mg, 300mg
    Quantity limitQL(360 EA per 30 days)
    TierTier = 1 (per table)
    gabapentin solution 250mg/5ml — 2160 ML
    ProductGabapentin solution 250mg/5ml
    Quantity limitQL(2160 ML per 30 days)
    TierTier = 4 (per table)
    pregabalin capsule 300mg — 60 EA
    ProductPregabalin capsule 300mg
    Quantity limitQL(60 EA per 30 days)
    TierTier = 2 (per table)
    pregabalin other strengths — 90 EA
    ProductPregabalin other strengths
    Quantity limitQL(90 EA per 30 days)
    TierTier = 2 (per table)
    memantine/donepezil er capsule combination — 30 EA
    ProductMemantine/donepezil ER capsule combination
    Quantity limitQL(30 EA per 30 days)
    TierTier = 3 (per table)
    desvenlafaxine er 100mg — 120 EA
    ProductDesvenlafaxine ER 100mg
    Quantity limitQL(120 EA per 30 days)
    TierTier = 2 (per table)
    ZURZUVAE CAPSULE 30MG — QL(14 EA per 14 days)
    ProductZURZUVAE CAPSULE 30MG
    Quantity limitQL(14 EA per 14 days)
    Requirement notePA NSO indicated for ZURZUVAE entries
    ZURZUVAE CAPSULE 20MG, 25MG — QL(28 EA per 14 days)
    ProductZURZUVAE CAPSULE 20MG, 25MG
    Quantity limitQL(28 EA per 14 days)
    Requirement notePA NSO indicated for ZURZUVAE entries
    desvenlafaxine ER 100mg — QL(120 EA per 30 days)
    ProductDesvenlafaxine ER 100mg
    Quantity limitQL(120 EA per 30 days)
    TierTier = 2 (per table)
    desvenlafaxine ER 25mg, 50mg — QL(30 EA per 30 days)
    ProductDesvenlafaxine ER 25mg, 50mg
    Quantity limitQL(30 EA per 30 days)
    TierTier = 2 (per table)
    DRIZALMA SPRINKLE 20mg, 60mg — QL(60 EA per 30 days)
    ProductDRIZALMA SPRINKLE 20mg, 60mg
    Quantity limitQL(60 EA per 30 days)
    TierTier = 4 (per table)
    DRIZALMA SPRINKLE 30mg, 40mg — QL(90 EA per 30 days)
    ProductDRIZALMA SPRINKLE 30mg, 40mg
    Quantity limitQL(90 EA per 30 days)
    TierTier = 4 (per table)
    duloxetine DR 20mg, 60mg — QL(60 EA per 30 days)
    ProductDuloxetine DR 20mg, 60mg
    Quantity limitQL(60 EA per 30 days)
    TierTier = 2 (per table)
    duloxetine DR 30mg — QL(90 EA per 30 days)
    ProductDuloxetine DR 30mg
    Quantity limitQL(90 EA per 30 days)
    TierTier = 2 (per table)
    FETZIMA TITRATION PACK — QL(56 EA per 365 days)
    ProductFETZIMA TITRATION PACK
    Quantity limitQL(56 EA per 365 days)
    TierTier = 4 (per table)
    FETZIMA CAPSULE ER — QL(30 EA per 30 days)
    ProductFETZIMA CAPSULE ER (20/40/80/120mg)
    Quantity limitQL(30 EA per 30 days)
    TierTier = 4 (per table)
    TRINTELLIX TABLET — QL(30 EA per 30 days)
    ProductTRINTELLIX TABLET (5/10/20mg)
    Quantity limitQL(30 EA per 30 days)
    TierTier = 4 (per table)

    Mail Order & Long-Term Care (LTC) Guidance

    Note

    Definitions & Requirements/Limits Key

    Note

    Background & Scope

    This formulary groups drugs by condition and shows the assigned tier and any Requirements/Limits for each product. If a listed product has utilization controls (for example, PA for prior authorization or QL(...) indicating a quantity limit) those flags appear in the Requirements/Limits column and must be followed. To request an exception when a drug is not covered or when a required authorization is needed, contact Customer Service and follow the plan’s exception/authorization process described in the formulary materials.